Leukemia
Research from Northwestern University, Department of Pediatric Hematology-Oncology provides new data on leukemia in children
Published in Cancer Weekly, January 5th, 2010
Current study results from the report, 'A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia,' have been published. "This Phase I study of clofarabine with etoposide and cyclophosphamide for children with relapsed/refractory acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML) was conducted to determine the maximum tolerated dose (MTD), dose-limiting toxicities and the recommended phase 2 doses (RP2Ds). All three drugs were administered for five consecutive days in induction and four consecutive days in consolidation, for a maximum of eight cycles," scientists writing in...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2010-01-05)
More Articles from Cancer Weekly
- Burnham Institute
Delivering medicine directly into a tumor - Columbia University's Mailman School of Public Health
Cancer survival disparities for most minority populations increase as cancers become more treatable - Federation of American Societies for Experimental Biology
Scientists take important step toward the proverbial fountain of youth - Journal of the National Cancer Institute
High risk of colorectal, endometrial and Lynch syndrome cancers for MSH6 mutation carriers - Journal of the National Cancer Institute
News brief: Relatives of boys with sexual birth defects not at risk for testicular germ cell cancer - New York Medical College
Research suggests link between infertility, low egg reserve, and breast/ovarian cancer gene BRCA1 - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
